Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.50 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29729443 | 1.00 | LMNA (0.58) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL201122 | 0.86 | HTR1A (0.58) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL29362202 | 0.86 | HTR1A (0.58) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL28581110 | 0.81 | LMNA (0.61) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL1496335 | 0.80 | LMNA (0.59) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL28810851 | 0.79 | MTNR1A (0.49) | LMNAKDM4EMAPK1NPSR1MTNR1A | |
| SCHEMBL11767672 | 0.79 | LMNA (0.58) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL18544268 | 0.79 | KDM4E (0.60) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL591852 | 0.79 | LMNA (0.62) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL590225 | 0.79 | LMNA (0.58) | LMNAKDM4EHTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084779-A | 4-Substituted quinoline amino acid conjugate and preparation method and application thereof | 天津科技大学 | 2024-05-28 | — | — | CN | claimed |
| US-6903217-B2 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-06-07 | — | — | US | claimed |
| US-3989691-A | FROM A QUINOLINE | PRINCETON UNIVERSITY (US) | 1976-11-02 | — | — | US | claimed |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4622970-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-119081100-A | FAPi, FAPi intermediate, FAPi modified lipid nanoparticle for encapsulating HSP47 siRNA and application of lipid nanoparticle | 华东师范大学 | 2024-12-06 | — | — | CN | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-1998022457-A9 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022457-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5506235-A | Quinoline derivatives as immunostimulants | PFIZER INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0597003-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0240859-B1 | LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1993003030-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| US-4761403-A | QUINOLONE DERIVATIVES | ABBOTT LABORATORIES (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0240859-A2 | Lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1987-10-14 | — | — | EP | disclosed |
| US-3989691-A | FROM A QUINOLINE | PRINCETON UNIVERSITY (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | LMNA 1704/4885KDM4E 4744/4885HTR1A 267/4885 |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | RIPK1, RIPK2, RIPK4 | LMNA 2558/4885KDM4E 2182/4885HTR1A 3996/4885 |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | LMNA 1113/4885KDM4E 4052/4885HTR1A 570/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LMNA 1762/4885KDM4E 1863/4885HTR1A 813/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | LMNA 2921/4885KDM4E 3070/4885HTR1A 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.